Spotlight on rare NMOSD: Chord launches with $16m Series A round
Omega Funds has backed Chord Therapeutics with $16m Series A funding. This money will be used to advance CRD1, Chord’s…
By
Omega Funds has backed Chord Therapeutics with $16m Series A funding. This money will be used to advance CRD1, Chord’s…
ByPP2A has long been recognised as a promising target in oncology, but it has remained elusive to scientists. Helsinki-based Rappta…
ByPhenomic AI has secured $6m in seed funding, which it plans to use to advance its two lead candidates into…
ByEir Ventures and Soleus Capital have co-led a $64m equity financing into Galecto and its novel approach to tackling fibrosis.…
ByAfter raising $45m in a successful Series A round, Graphite has launched with its next-generation gene editing platform. How does…
ByLumen Bioscience has raised $16m in a Series B financing round to support its clinical programmes in prevalent but overlooked…
ByForge has completed a $40m Series A round, led by the PXV Fund, which will be enable the company to…
BySwiss biotech iOnctura has closed a Series A round with €20.1m raised. The round was supported by existing investors –…
By